Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Oragenics, Inc. Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards April 19, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics, Inc. Files 10K and Provides Company Update April 01, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion March 18, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion March 05, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Announces Closing of Public Offering March 01, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Announces Pricing of Public Offering February 27, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Announces Proposed Public Offering February 27, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics, Inc. Announces Leadership Transition February 12, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement February 07, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion February 05, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Announces Termination of At-The-Market Offering Program January 23, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets January 02, 2024 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors October 18, 2023 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate October 05, 2023 From Oragenics, Inc. Via Business Wire Tickers ODYY OGEN Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets September 29, 2023 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics, Inc. Announces Private Placement August 07, 2023 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM June 05, 2023 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics to Participate in the World Vaccine Congress Washington March 29, 2023 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE March 14, 2023 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team March 08, 2023 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate March 01, 2023 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics, Inc. Regains Compliance with NYSE American February 03, 2023 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split December 23, 2022 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate December 22, 2022 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics, Inc. Receives NYSE American Notice December 20, 2022 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics, Inc. Announces New Chair December 19, 2022 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics to Participate in the 2022 BioFlorida Annual Conference October 24, 2022 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Issues Letter to Shareholders September 30, 2022 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate August 24, 2022 From Oragenics, Inc. Via Business Wire Tickers OGEN Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer June 23, 2022 From Oragenics, Inc. Via Business Wire Tickers OGEN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.